Research Coverage Initiated for UroGen Pharma by LADENBURG THALM/SH SH

On February 22, 2025, LADENBURG THALM/SH SH announced the commencement of research coverage on UroGen Pharma (NASDAQ:URGN) in their latest report. The firm has assigned a "buy" rating to the stock, along with a price target of $31.00.

In a related note, D. Boral Capital also reaffirmed a "buy" rating for UroGen Pharma, setting a price target of $25.00. According to data from MarketBeat, five investment analysts currently recommend the stock as a buy, while one analyst has given it a strong buy rating. The average rating received for the stock is "Buy," and the average price target stands at $39.20.

Recent Performance of UroGen Pharma

On the day of the report, UroGen Pharma shares opened at $10.08, reflecting a decline of 5.9%. The company possesses a current ratio of 9.00 and a quick ratio of 8.77, with a debt-to-equity ratio measured at 4.77. The stock's 50-day moving average is $10.73, while the 200-day moving average is $12.20. UroGen Pharma has recorded a twelve-month low of $9.78 and a high of $20.70. Presently, the company's market capitalization is approximately $236.38 million, with a price-to-earnings (P/E) ratio of -3.20 and a beta of 1.08.

Insider Transactions

In recent corporate activities, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma on January 31, which amounted to a transaction value of $50,698.14 at an average price of $11.14. After the trade, Schoenberg's remaining shares total 145,666, valued at approximately $1,622,719.24, representing a 3.03% drop in his position. Additionally, General Counsel Jason Drew Smith disposed of 7,379 shares on the same day for a total of $82,202.06. Post-sale, Smith holds 26,468 shares, valued at around $294,853.52, reflecting a 21.80% reduction in his stake. Insider ownership within the company stands at 5.10%.

Institutional Holdings Update

Hedge funds have recently made significant adjustments to their holdings in UroGen Pharma. KLP Kapitalforvaltning AS established a new position in the fourth quarter worth $59,000. Lazard Asset Management LLC made a similar move, acquiring shares valued at $67,000. In the third quarter, China Universal Asset Management Co. Ltd. increased their stake in UroGen Pharma by 90.9%, now owning 8,100 shares after adding 3,856 shares during the last quarter. BNP Paribas Financial Markets also increased their position by 221.8% in the third quarter, now holding 8,546 shares, valued at $109,000. Furthermore, Aquatic Capital Management LLC acquired a new stake worth $101,000 in the fourth quarter. Institutional and hedge fund investors collectively own 91.29% of UroGen Pharma's stock.

About UroGen Pharma

UroGen Pharma Ltd. is a biotechnology firm that focuses on developing and commercializing treatments for urothelial and specialty cancers. The company offers RTGel, which is an innovative proprietary polymeric biocompatible technology designed to enhance the therapeutic profiles of existing medications, alongside Jelmyto, a solution for pyelocalyceal applications.

Further Reading

• Five stocks we like better than UroGen Pharma
• Canadian Penny Stocks: Can They Make You Rich?
• 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
• Breakout Stocks: What They Are and How to Identify Them
• MercadoLibre: High-Growth EM Stock With 100% Upside Potential
• Manufacturing Stocks Investing
• As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum

Stay Updated on UroGen Pharma - To receive daily summaries of the latest news and analyst ratings for UroGen Pharma and related companies, consider subscribing to a free email newsletter.

UroGen, Pharma, Stocks